Benefits
Joint comfort in osteoarthritis
ParActin® clinical trials document joint comfort improvements in adults with osteoarthritis. Effect sizes meaningful as natural anti-inflammatory alternative to NSAIDs. Specifically trial-validated for this branded form.
PPAR-gamma activation mechanism
ParActin® andrographolides activate PPAR-gamma — the same nuclear receptor target as some diabetes medications (thiazolidinediones). The mechanism explains the anti-inflammatory and metabolic effects through a distinct pathway from typical anti-inflammatory supplements.
Anti-inflammatory biomarker effects
Clinical trials document ParActin® reduces inflammatory cytokines and biomarkers in adults with chronic inflammation. The mechanism-specific characterization supports use in inflammation-driven conditions.
Immune system modulation
ParActin® supports balanced immune function — reducing excessive inflammation while supporting appropriate immune response. The immunomodulatory effects support both joint and respiratory applications.
Standardization advantage
ParActin® provides reproducible andrographolide content batch-to-batch through quality control. Generic andrographis extracts vary dramatically in actual andrographolide content; ParActin® addresses this through verified standardization.
Clinical trial validation
Multiple ParActin® clinical trials document effects on joint comfort, inflammation, and immune function. The trial-validated branded form distinguishes from generic andrographis with less specific characterization.
Mechanism of action
PPAR-gamma nuclear receptor activation
ParActin® andrographolides activate PPAR-gamma receptors, modulating gene expression for inflammation, metabolism, and immune function. Distinguishing mechanism from typical anti-inflammatory supplements.
NF-κB pathway modulation
Andrographolides reduce NF-κB activation and downstream pro-inflammatory cytokine production. Mechanism contributes to the broad anti-inflammatory effects.
Standardized bioavailability
ParActin® standardization produces reproducible plasma andrographolide levels and downstream tissue effects. Important for consistent clinical outcomes.
Clinical trials
ParActin® clinical trials document joint comfort improvements in adults with osteoarthritis. Effect sizes meaningful for natural anti-inflammatory positioning.
Clinical studies document ParActin® reduces inflammatory cytokines and biomarkers. Mechanism-specific characterization supports use in inflammation-driven conditions.
Quality control studies validate ParActin® batch-to-batch consistency. Long-term safety established through clinical trial use.